CAM
ADPT icon

Close Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Close Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15
Closed – – 196
2022
Q3 		$0 Hold
15
– – ﹤0.01% 183
2022
Q2 		$0 Sell
15
-1,485
-99% -$13.1K ﹤0.01% 188
2022
Q1 		$42K Hold
1,500
– – ﹤0.01% 132
2021
Q4 		$42K Hold
1,500
– – ﹤0.01% 132
2021
Q3 		$51K Sell
1,500
-3,100
-67% -$112K ﹤0.01% 120
2021
Q2 		$188K Buy
+4,600
New +$179K 0.01% 98

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Close Asset Management's ADPT Position: Q4 2022 in Review

Close Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2022, closing a stake of 15 shares.

Close Asset Management first reported a position in ADPT in Q2 2021 and held it in 6 quarters. The position peaked at $188K in Q2 2021. 223 funds tracked by Wall St. Rank hold ADPT as of Q4 2022.

  • Close Asset Management reported no remaining Adaptive Biotechnologies position as of Q4 2022 after selling out during the quarter.
  • Close Asset Management sold 15 Adaptive Biotechnologies shares in Q4 2022.
  • Close Asset Management first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 6 quarters.
  • Close Asset Management's Adaptive Biotechnologies position peaked at $188K in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2022.

Based on Close Asset Management's 13F filing for Q4 2022, filed 27 Jan 2023.